WO2010148209A3 - Preparation of montelukast - Google Patents

Preparation of montelukast Download PDF

Info

Publication number
WO2010148209A3
WO2010148209A3 PCT/US2010/039010 US2010039010W WO2010148209A3 WO 2010148209 A3 WO2010148209 A3 WO 2010148209A3 US 2010039010 W US2010039010 W US 2010039010W WO 2010148209 A3 WO2010148209 A3 WO 2010148209A3
Authority
WO
WIPO (PCT)
Prior art keywords
montelukast
preparation
salts
processes
Prior art date
Application number
PCT/US2010/039010
Other languages
French (fr)
Other versions
WO2010148209A2 (en
Inventor
Martin Edward Fox
Satyanarayana Bollikonda
Saravanan Mohanarangam
Rajender Reddy Jinna
Venkata Kiran Kumar Kandirelli
Original Assignee
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc. filed Critical Dr. Reddy's Laboratories Ltd.
Publication of WO2010148209A2 publication Critical patent/WO2010148209A2/en
Publication of WO2010148209A3 publication Critical patent/WO2010148209A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Processes for the preparation of montelukast and its salts.
PCT/US2010/039010 2009-06-19 2010-06-17 Preparation of montelukast WO2010148209A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1453/CHE/2009 2009-06-19
IN1453CH2009 2009-06-19
US29261310P 2010-01-06 2010-01-06
US61/292,613 2010-01-06

Publications (2)

Publication Number Publication Date
WO2010148209A2 WO2010148209A2 (en) 2010-12-23
WO2010148209A3 true WO2010148209A3 (en) 2011-08-04

Family

ID=43357052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/039010 WO2010148209A2 (en) 2009-06-19 2010-06-17 Preparation of montelukast

Country Status (1)

Country Link
WO (1) WO2010148209A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012320010B2 (en) * 2011-07-26 2017-03-30 Sun Pharma Advanced Research Company Ltd. Quinoline-, quinoxaline or benzothiazole based cysteinyl leukotriene antagonists (LTD4)
CN102424673B (en) * 2011-09-14 2013-12-04 浙江海正药业股份有限公司 Montelukast sodium intermediate and method for synthesizing montelukast sodium thereof
WO2014081616A1 (en) * 2012-11-21 2014-05-30 Merck Sharp & Dohme Corp. Preparation of precursors for leukotriene antagonists
CN104109123B (en) * 2013-04-16 2016-12-07 浙江奥翔药业股份有限公司 For midbody compound synthesizing montelukast and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614632A (en) * 1993-12-28 1997-03-25 Merck & Co., Inc. Process for the preparation of leukotriene anatgonists
WO2004108679A1 (en) * 2003-06-06 2004-12-16 Morepen Laboratories Limited An improved method for the preparation of montelukast acid and sodium salt thereof in amorphous form
WO2006058545A1 (en) * 2004-11-30 2006-06-08 Medichem, S.A. New process for the preparation of a leukotriene antagonist
WO2008126075A1 (en) * 2007-04-12 2008-10-23 Chemagis Ltd. Process for preparing montelukast and salts thereof using optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl)phenyl-2-propanol
US7528254B2 (en) * 2006-02-27 2009-05-05 Chemagis Ltd. Process for preparing montelukast and salts thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614632A (en) * 1993-12-28 1997-03-25 Merck & Co., Inc. Process for the preparation of leukotriene anatgonists
WO2004108679A1 (en) * 2003-06-06 2004-12-16 Morepen Laboratories Limited An improved method for the preparation of montelukast acid and sodium salt thereof in amorphous form
WO2006058545A1 (en) * 2004-11-30 2006-06-08 Medichem, S.A. New process for the preparation of a leukotriene antagonist
US7528254B2 (en) * 2006-02-27 2009-05-05 Chemagis Ltd. Process for preparing montelukast and salts thereof
WO2008126075A1 (en) * 2007-04-12 2008-10-23 Chemagis Ltd. Process for preparing montelukast and salts thereof using optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl)phenyl-2-propanol

Also Published As

Publication number Publication date
WO2010148209A2 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
WO2013046060A9 (en) Paper and methods of making paper
EP2629975A4 (en) Devices, systems, and methods for the fabrication of tissue
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2010117738A3 (en) Solid state forms of sitagliptin salts
EP2729464B8 (en) Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors
EP2604646A4 (en) Microporous film, process for production of the film, and use of the film
EP2210618B8 (en) Isolator
WO2010056656A3 (en) Preparation of crystalline palonosetron hydrochloride
WO2009117381A3 (en) Preparation of montelukast and its salts
WO2011139886A3 (en) Preparation of febuxostat
IL196602A0 (en) Processes for the preparation of montelukast
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
IL221184A (en) Process for the preparation of 5-substituted 1-alkyltetrazoles
WO2010148209A3 (en) Preparation of montelukast
EP2509708B8 (en) Silicon phosphate and membrane comprising the same
WO2010109185A3 (en) Process for the preparation of doxazosin and salts thereof
EP2571836A4 (en) Process for the preparation of hexafluoro-2-butyne
WO2012046250A8 (en) Polymorphic forms of o-desmethyl-venlafaxine succinate
WO2013009678A3 (en) Compositions and methods for the treatment of norovirus infection
EP2467375A4 (en) Forms of dexlansoprazole and processes for the preparation thereof
WO2013003547A3 (en) Bhq-conjugates, and related compounds, methods of making the same, and methods of use thereof
EP2544534A4 (en) Compositions, methods, and devices for the treatment of dysmenorrhea
AU2010101098A4 (en) Shadowline 52mm
AU2010901169A0 (en) Stop collar
AU2009903493A0 (en) The Jab System

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10790198

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 9433/CHENP/2011

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10790198

Country of ref document: EP

Kind code of ref document: A2